A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Apollo Therapeutics Ltd
280 participants
May 28, 2026
INTERVENTIONAL
Conditions
Summary
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Drug Product
Inactive substance
Locations(85)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07599813